Intrinsic Value
Karyopharm Therapeutics Inc. · KPTI
Conservative
More adverse but historically defensible assumptions.
-$80.35
Base
The model's central intrinsic-value estimate.
-$119.42
Optimistic
More favorable but historically defensible assumptions.
-$269.29
Scenarios are the same model run under different but historically defensible assumptions. They are not price targets. Where a valuation gap is shown it is a comparison with a recent close, not a forecast return; where the price is stale, no gap is shown at all.
Model confidence: 70%Valuation as of Sep 21, 2026Latest filing used Feb 13, 2026
Confidence reflects data completeness, accounting quality, and model reliability. It is not a probability of future price.
Valuation drivers
- Normalized operating margin
- -90.5%
- Normalized NOPAT margin
- -70.4%
- Revenue growth
- 0.6%
- WACC
- 8.23%
- Terminal growth
- 0.57%
- Reinvestment method
- incremental roic
- Terminal-value share
- 48.0%
Model notes (2)
- Interest-bearing debt unavailable
- Minority interest not reported
Model details
- Normalization
- V1
- Scenario
- V2
- Confidence
- V1
- Engine version
- valuation-1.0.1-share-units-terminal
- Data snapshot
- filed:2026-02-13